Upgrade to SI Premium - Free Trial

Momenta/Sandoz Generic Copaxone Already Accounted for in Teva (TEVA) Estimates - Guggenheim

February 13, 2018 6:27 AM
Guggenheim's Teva Pharma (NYSE: TEVA) analyst Rohit Vanjani notes Momenta/Sandoz finally received approval of its gCopaxone ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments FDA

Next Articles